KR20210046843A - 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법 - Google Patents

알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법 Download PDF

Info

Publication number
KR20210046843A
KR20210046843A KR1020217011613A KR20217011613A KR20210046843A KR 20210046843 A KR20210046843 A KR 20210046843A KR 1020217011613 A KR1020217011613 A KR 1020217011613A KR 20217011613 A KR20217011613 A KR 20217011613A KR 20210046843 A KR20210046843 A KR 20210046843A
Authority
KR
South Korea
Prior art keywords
alkyl
phenyl
autism
glyx
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217011613A
Other languages
English (en)
Korean (ko)
Inventor
요셉 모스칼
Original Assignee
노오쓰웨스턴 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노오쓰웨스턴 유니버시티 filed Critical 노오쓰웨스턴 유니버시티
Publication of KR20210046843A publication Critical patent/KR20210046843A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217011613A 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법 Ceased KR20210046843A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161479593P 2011-04-27 2011-04-27
US61/479,593 2011-04-27
US201161527744P 2011-08-26 2011-08-26
US61/527,744 2011-08-26
PCT/US2012/035547 WO2012149389A2 (en) 2011-04-27 2012-04-27 Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207011211A Division KR20200043534A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법

Publications (1)

Publication Number Publication Date
KR20210046843A true KR20210046843A (ko) 2021-04-28

Family

ID=47073094

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020217011613A Ceased KR20210046843A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020187022910A Ceased KR20180095096A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020197008907A Ceased KR20190037359A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020207011211A Ceased KR20200043534A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020137031028A Ceased KR20140043078A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020187022910A Ceased KR20180095096A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020197008907A Ceased KR20190037359A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020207011211A Ceased KR20200043534A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
KR1020137031028A Ceased KR20140043078A (ko) 2011-04-27 2012-04-27 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법

Country Status (13)

Country Link
US (4) US20140107037A1 (https=)
EP (2) EP2701721A4 (https=)
JP (1) JP6035326B2 (https=)
KR (5) KR20210046843A (https=)
CN (2) CN103974712A (https=)
AU (1) AU2012249397B2 (https=)
BR (1) BR112013027554A2 (https=)
CA (1) CA2834286A1 (https=)
EA (2) EA029999B1 (https=)
HK (1) HK1258231A1 (https=)
MX (1) MX357761B (https=)
SG (2) SG10202010665YA (https=)
WO (1) WO2012149389A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011003015A (es) 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
CN105037492A (zh) 2010-02-11 2015-11-11 西北大学 二级结构稳定化的nmda受体调节剂及其用途
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
KR20150110787A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
EA032649B1 (ru) 2013-01-29 2019-06-28 Аптиникс Инк. Спиролактамные модуляторы nmda-рецептора и их применение
SG11201505862TA (en) 2013-01-29 2015-08-28 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
SG11201505942YA (en) 2013-01-29 2015-08-28 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
KR20150110586A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
AU2014342624A1 (en) * 2013-10-28 2016-06-02 Naurex, Inc. NMDA receptor modulators and prodrugs, salts, and uses thereof
MX2016007716A (es) * 2013-12-13 2017-03-31 Univ Northwestern Metodos para el tratamiento de trastornos cerebrales o la identificacion de biomarcadores relacionados con estos.
CN105327349A (zh) * 2014-06-18 2016-02-17 上海翰森生物医药科技有限公司 Nmda受体拮抗剂的医药用途及其药物组合物
CN106661085A (zh) * 2014-06-23 2017-05-10 西北大学 治疗或改善偏头痛的方法
JP2018530593A (ja) * 2015-10-16 2018-10-18 ノースウェスタン ユニバーシティ 統合失調症、双極性障害、認知障害及び大うつ病性障害の治療のための非定型的抗精神病薬ならびにｎｍｄａ調節剤の医薬品の組み合わせ
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
BR112018073663A2 (pt) 2016-05-19 2019-04-30 Aptinyx Inc. moduladores de receptores nmda spiro-lactâmicos e seus usos
WO2018026782A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
SG10202101055VA (en) 2016-08-01 2021-03-30 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
JP2019527232A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタムｎｍｄａ修飾因子及びこれを用いた方法
MX385336B (es) 2016-08-01 2025-03-18 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos.
EP3490994B8 (en) 2016-08-01 2024-03-13 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
CN112204031B (zh) 2018-01-31 2024-05-24 元羿生物科技(香港)有限公司 螺-内酰胺nmda受体调节剂及其用途
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
KR102415692B1 (ko) 2020-09-01 2022-07-05 건국대학교 글로컬산학협력단 시냅스 불균형 조절에 의한 발달장애 예방, 개선 또는 치료용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
GB0018272D0 (en) * 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
EP1471909A4 (en) * 2002-01-16 2007-07-25 Endo Pharmaceuticals Inc PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
WO2006034196A1 (en) * 2004-09-17 2006-03-30 Lifelike Biomatic Inc. Compositions for enhancing memory and methods therefor
US20090325920A1 (en) * 2005-03-24 2009-12-31 Emory University Methods for the treatment of a traumatic central nervous system injury
WO2009105718A1 (en) * 2008-02-20 2009-08-27 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism
MX2011003015A (es) * 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
PL2485751T3 (pl) * 2009-10-05 2014-10-31 Univ Northwestern GLYX-13 do stosowania w sposobie leczenia depresji opornej na leczenie

Also Published As

Publication number Publication date
EA029999B1 (ru) 2018-06-29
KR20180095096A (ko) 2018-08-24
US20170049845A1 (en) 2017-02-23
WO2012149389A3 (en) 2014-05-08
EP2701721A2 (en) 2014-03-05
US20190209642A1 (en) 2019-07-11
CA2834286A1 (en) 2012-11-01
EA201790653A1 (ru) 2017-07-31
EP2701721A4 (en) 2015-12-16
AU2012249397A1 (en) 2013-11-07
AU2012249397B2 (en) 2017-03-30
JP2014520072A (ja) 2014-08-21
EP3679931A2 (en) 2020-07-15
SG194230A1 (en) 2013-12-30
EA201391581A1 (ru) 2014-05-30
KR20140043078A (ko) 2014-04-08
MX357761B (es) 2018-07-23
MX2013012526A (es) 2014-04-16
JP6035326B2 (ja) 2016-11-30
SG10202010665YA (en) 2020-11-27
KR20200043534A (ko) 2020-04-27
HK1258231A1 (zh) 2019-11-08
US20210169964A1 (en) 2021-06-10
WO2012149389A2 (en) 2012-11-01
BR112013027554A2 (pt) 2016-09-06
KR20190037359A (ko) 2019-04-05
US20140107037A1 (en) 2014-04-17
CN108283712A (zh) 2018-07-17
CN103974712A (zh) 2014-08-06
EP3679931A3 (en) 2020-10-14

Similar Documents

Publication Publication Date Title
KR20210046843A (ko) 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
Maden Retinoic acid in the development, regeneration and maintenance of the nervous system
Costantin et al. Antiepileptic effects of botulinum neurotoxin E
Verhave et al. Neuroprotective effects of riluzole in early phase Parkinson's disease on clinically relevant parameters in the marmoset MPTP model
CN115209908A (zh) 具有神经保护、免疫调节、抗炎和抗微生物活性的基于蛋白质的药学组合物
EP0782573B1 (en) Brefeldin a and analogs to improved synaptic transmission
Yanamoto et al. Repeated application of an electric field increases BDNF in the brain, enhances spatial learning, and induces infarct tolerance
HK40034037A (en) Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders
Razumovskaya et al. Modulation of nicotinic receptors in neurons in the common snail by Noopept and Piracetam
Asahina et al. AAV9-mediated NGLY1 gene replacement suppresses non-epileptic convulsions in Ngly1-/-rats
Gardner et al. The neurobiology of nicotine addiction: Clinical and public policy implications
EP2332530B1 (en) The use of potassium 2-(hydroxypentyl) benzoate in the manufacture of medicaments for preventing and/or treating senile dementia
Wheeler Functional recovery following spinal cord injury: remyelination as a therapeutic target in aging
CN112807435A (zh) 酸敏感离子通道调控剂的用途
KR20200018955A (ko) Grp75 단백질을 유효성분으로 포함하는 신경 손상 질환 예방 또는 치료용 조성물
Kawahara et al. Ghrelin restores D1 receptor-mediated dopamine neurotransmission and enhances attentive behaviour in Mecp2 KO mice
Loan et al. Treatment options in motor neuron disease: Amyotrophic lateral sclerosis and spinal muscular atrophy
Mewes Establishment of a viral vector-mediated animal model for Parkinson's disease and evaluation of the transduction potential of FGF-2 isoforms in vitro
Bonifacino et al. Alterations of Synaptic Mechanisms and Excessive Glutamate Release in the Spinal Cord of SOD1G93A Mice
Potey et al. N-Methyl-d-Aspartate Receptors Remain Viable Therapeutic Targets for Stroke
Clelland A functional role of mammalian adult hippocampal neurogenesis in the normal and diseased brain
TW201929850A (zh) 醫藥組成物於製備預防或治療不正常乙型-澱粉樣蛋白聚集類疾病之藥物上之用途
Pirttilä Expression and functions of cystatin C in epileptogenesis and epilepsy
Reijak Investigation of strategies to ameliorate beta-amyloid mediated deficits in hippocampus-dependent synaptic plasticity
최영준 Oral sensory alteration affects psycho-emotional behaviors in rats

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210419

Application number text: 1020207011211

Filing date: 20200417

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210518

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210601

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210820

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210601

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I